Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 4
Submit an article Journal homepage
485
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Towards Personalized Medicine

Maša Umićević Mirkov1 .Department of Human Genetics, Radboud University Medical Centre, PO Box 9101>, 6500 HBNijmegen, The Netherlands
&
Marieke JH Coenen1 .Department of Human Genetics, Radboud University Medical Centre, PO Box 9101>, 6500 HBNijmegen, The NetherlandsCorrespondence[email protected]
Pages 425-444 | Published online: 25 Feb 2013

References

  • Lee DM , WeinblattME. Rheumatoid arthritis. Lancet358(9285) , 903–911 (2001).
  • Gabriel SE , MichaudK. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther.11(3) , 229 (2009).
  • Gonzalez A , Maradit Kremers H, Crowson CS et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum.56(11) , 3583–3587 (2007).
  • Schipper LG , VermeerM, KuperHH et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann. Rheum. Dis. 71(6) , 845–850 (2012).
  • Smolen JS , LandeweR, BreedveldFC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6) , 964–975 (2010).
  • Singh JA , FurstDE, BharatA et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64(5) , 625–639 (2012).
  • Prevoo ML , van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified Disease Activity Scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum.38(1) , 44–48 (1995).
  • Felson DT , AndersonJJ, BoersM et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38(6) , 727–735 (1995).
  • Smolen JS , AletahaD, KoellerM, WeismanMH, EmeryP. New therapies for treatment of rheumatoid arthritis. Lancet370(9602) , 1861–1874 (2007).
  • Kirwan JR , BijlsmaJW, BoersM, SheaBJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst. Rev.1 , CD006356 (2007).
  • Van Vollenhoven RF . Treatment of rheumatoid arthritis: state of the art 2009. Nat. Rev. Rheumatol.5(10) , 531–541 (2009).
  • Bingham CO 3rd. Emerging therapeutics for rheumatoid arthritis. Bull. NYU Hosp. Jt Dis.66(3) , 210–215 (2008).
  • Pincus T , YaziciY, SokkaT, AletahaD, SmolenJS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol.21(5 Suppl. 31) , S179–185 (2003).
  • Salliot C , Van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum. Dis.68(7) , 1100–1104 (2009).
  • Breedveld FC , WeismanMH, KavanaughAF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1) , 26–37 (2006).
  • Emery P , BreedveldFC, HallS et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636) , 375–382 (2008).
  • Hider SL , BruceIN, ThomsonW. The pharmacogenetics of methotrexate. Rheumatology46(10) , 1520–1524 (2007).
  • Ranganathan P . An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics9(4) , 439–451 (2008).
  • Drozdzik M , RudasT, PawlikA, GornikW, KurzawskiM, HerczynskaM. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J.7(6) , 404–407 (2007).
  • Hayashi H , TazoeY, TsuboiS et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab. Pharmacokinet. doi:10.2133/dmpk.DMPK-12-NT-038 (2012) (Epub ahead of print).
  • Dervieux T , KremerJ, LeinDO et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14(11) , 733–739 (2004).
  • Bohanec Grabar P , LogarD, LestanB, DolzanV. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol.64(11) , 1057–1068 (2008).
  • Takatori R , TakahashiKA, TokunagaD et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol.24(5) , 546–554 (2006).
  • Wessels JA , de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum.54(4) , 1087–1095 (2006).
  • Dervieux T , GreensteinN, KremerJ. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum.54(10) , 3095–3103 (2006).
  • Kato T , HamadaA, MoriS, SaitoH. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab. Pharmacokinet.27(2) , 192–199 (2012).
  • Lee YC , CuiJ, CostenbaderKH, ShadickNA, WeinblattME, KarlsonEW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology48(6) , 613–617 (2009).
  • Plaza-Plaza JC , AguileraM, Canadas-GarreM et al. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. OMICS 16(11) , 589–595 (2012).
  • Pawlik A , WrzesniewskaJ, Fiedorowicz-FabrycyI, Gawronska-SzklarzB. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther.42(9) , 496–503 (2004).
  • Drozdzik M , RudasT, PawlikA et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol. 62(11) , 933–937 (2006).
  • Sharma S , DasM, KumarA et al. Interaction of genes from influx–metabolism–efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet. Genomics 18(12) , 1041–1049 (2008).
  • Kooloos WM , WesselsJA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics11(2) , 163–175 (2010).
  • Stamp LK , ChapmanPT, O‘DonnellJL et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet. Genomics 20(6) , 367–376 (2010).
  • Ranganathan P , CulverhouseR, MarshS et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol. 35(4) , 572–579 (2008).
  • Owen SA , HiderSL, MartinP, BruceIN, BartonA, ThomsonW. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. doi:10.1038/tpj.2012.7 (2012) (Epub ahead of print).
  • Cronstein BN . Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev.57(2) , 163–172 (2005).
  • Fisher MC , CronsteinBN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol.36(3) , 539–545 (2009).
  • Rozen R . Molecular genetics of methylenetetrahydrofolate reductase deficiency. J. Inherit. Metab. Dis.19(5) , 589–594 (1996).
  • Chango A , BoissonF, BarbeF et al. The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br. J. Nutr. 83(6) , 593–596 (2000).
  • Trembath D , SherbondyAL, VandykeDC et al. Analysis of select folate pathway genes, PAX3, and human T in a midwestern neural tube defect population. Teratology 59(5) , 331–341 (1999).
  • Owen SA , LuntM, BowesJ et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J. doi:10.1038/tpj.2011.42 (2011) (Epub ahead of print).
  • Spyridopoulou KP , DimouNL, HamodrakasSJ, BagosPG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet. Genomics22(2) , 117–133 (2012).
  • Lee YH , SongGG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin. Drug Investig.30(2) , 101–108 (2010).
  • Behrens F , KoehmM, BurkhardtH. Update 2011: leflunomide in rheumatoid arthritis – strengths and weaknesses. Curr. Opin. Rheumatol.23(3) , 282–287 (2011).
  • Olsen NJ , SteinCM. New drugs for rheumatoid arthritis. N. Engl. J. Med.350(21) , 2167–2179 (2004).
  • Pawlik A , HerczynskaM, KurzawskiM, SafranowK, DziedziejkoV, DrozdzikM. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics10(2) , 303–309 (2009).
  • Grabar PB , RozmanB, LogarD, PraprotnikS, DolzanV. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis.68(8) , 1367–1368 (2009).
  • O‘Doherty C , SchnablM, SpargoL et al. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics 13(12) , 1427–1434 (2012).
  • Kalgutkar AS , NguyenHT, VazAD et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726. mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos.31(10) , 1240–1250 (2003).
  • Bohanec Grabar P , RozmanB, TomsicM, SuputD, LogarD, DolzanV. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol.64(9) , 871–876 (2008).
  • Wiese MD , SchnablM, O‘DohertyC et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res. Ther. 14(4) , R163 (2012).
  • Gadangi P , LongakerM, NaimeD et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156(5) , 1937–1941 (1996).
  • Ladero JM . Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr. Drug Metab.9(6) , 532–537 (2008).
  • Tanaka E , TaniguchiA, UranoW et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J. Rheumatol. 29(12) , 2492–2499 (2002).
  • Wadelius M , StjernbergE, WiholmBE, RaneA. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics10(1) , 35–41 (2000).
  • Gregson A , PloweCV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev.57(1) , 117–145 (2005).
  • Pawlik A , KurzawskiM, GornikW, Dabrowska-ZamojcinE, DrozdzikM. 677C > T and 1298A > C MTHFR polymorphisms affect arechin treatment outcome in rheumatoid arthritis. Pharmacol. Rep.59(6) , 721–726 (2007).
  • Choy EH , PanayiGS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med.344(12) , 907–916 (2001).
  • Bathon JM , MartinRW, FleischmannRM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22) , 1586–1593 (2000).
  • Lipsky PE , van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.343(22) , 1594–1602 (2000).
  • Hyrich KL , LuntM, WatsonKD, SymmonsDP, Silman AJ; British Society for Rheumatology Biologics R. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum.56(1) , 13–20 (2007).
  • Cohen G , CourvoisierN, CohenJD, ZaltniS, SanyJ, CombeB. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin. Exp. Rheumatol.23(6) , 795–800 (2005).
  • Hetland ML , ChristensenIJ, TarpU et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62(1) , 22–32 (2010).
  • Furst DE , WallisR, BroderM, BeenhouwerDO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum.36(3) , 159–167 (2006).
  • Thalayasingam N , IsaacsJD. Anti-TNF therapy. Best Pract. Res. Clin. Rheumatol.25(4) , 549–567 (2011).
  • Taylor PC . Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol.10(3) , 308–315 (2010).
  • Bartelds GM , KrieckaertCL, NurmohamedMT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14) , 1460–1468 (2011).
  • Pascual-Salcedo D , PlasenciaC, RamiroS et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 50(8) , 1445–1452 (2011).
  • Cuchacovich M , SotoL, EdwardesM et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 35(6) , 435–440 (2006).
  • Louis E , FranchimontD, PironA et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin. Exp. Immunol. 113(3) , 401–406 (1998).
  • Lee YH , RhoYH, ChoiSJ, JiJD, SongGG. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol. Int.27(2) , 157–161 (2006).
  • O‘Rielly DD , RoslinNM, BeyeneJ, PopeA, RahmanP. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J.9(3) , 161–167 (2009).
  • Pavy S , ToonenEJ, Miceli-RichardC et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann. Rheum. Dis. 69(6) , 1022–1028 (2010).
  • Lee YH , JiJD, BaeSC, SongGG. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J. Rheumatol.37(4) , 740–746 (2010).
  • Cui J , SaevarsdottirS, ThomsonB et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 62(7) , 1849–1861 (2010).
  • Plant D , PrajapatiR, HyrichKL et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 64(3) , 665–670 (2012).
  • Krintel SB , PalermoG, JohansenJS et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 22(8) , 577–589 (2012).
  • Umićević Mirkov M , CuiJ, VermeulenSH et al. Genome-wide association analysis of anti-TNF drug response in rheumatoid arthritis patients. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202405 (2012) (Epub ahead of print).
  • Liu C , BatliwallaF, LiW et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14(9–10) , 575–581 (2008).
  • Suarez-Gestal M , Perez-PampinE, CalazaM, Gomez-ReinoJJ, GonzalezA. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res. Ther.12(2) , R72 (2010).
  • Plant D , BowesJ, PotterC et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 63(3) , 645–653 (2011).
  • Plenge RM , CriswellLA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr. Opin. Rheumatol.20(2) , 145–152 (2008).
  • Browning JL . B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov.5(7) , 564–576 (2006).
  • Edwards JC , SzczepanskiL, SzechinskiJ et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25) , 2572–2581 (2004).
  • Emery P , FleischmannR, Filipowicz-SosnowskaA et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54(5) , 1390–1400 (2006).
  • Cohen SB , EmeryP, GreenwaldMW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9) , 2793–2806 (2006).
  • Fabris M , QuartuccioL, LombardiS et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun. Rev. 11(5) , 315–320 (2012).
  • Robledo G , Davila-FajardoCL, MarquezA et al. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol. 31(9) , 1486–1491 (2012).
  • Kastbom A , CosterL, ArlestigL et al. Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open 2(5) , e001524 (2012).
  • Ruyssen-Witrand A , RouanetS, CombeB et al. Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann. Rheum. Dis. 71(6) , 875–877 (2012).
  • Fabris M , QuartuccioL, VitalE et al. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum. 65(1) , 88–97 (2012).
  • Daien CI , FabreS, RittoreC et al. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 79(5) , 471–475 (2012).
  • Bresnihan B , Alvaro-GraciaJM, CobbyM et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12) , 2196–2204 (1998).
  • Pociot F , MolvigJ, WogensenL, WorsaaeH, NerupJ. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest.22(6) , 396–402 (1992).
  • Cantagrel A , NavauxF, Loubet-LescoulieP et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum. 42(6) , 1093–1100 (1999).
  • Camp NJ , CoxA, Di Giovine FS, McCabe D, Rich W, Duff GW. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun.6(6) , 467–471 (2005).
  • Hennigan S , KavanaughA. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther. Clin. Risk Manag.4(4) , 767–775 (2008).
  • Wang J , BansalAT, MartinM et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. doi:10.1038/tpj.2012.8 (2012) (Epub ahead of print).
  • Kremer JM , GenantHK, MorelandLW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58(4) , 953–963 (2008).
  • Wessels JA , van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum.56(6) , 1765–1775 (2007).
  • Fransen J , KooloosWM, WesselsJA et al. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 13(9) , 1087–1094 (2012).
  • James HM , GillisD, HissariaP et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J. Rheumatol. 35(4) , 562–571 (2008).
  • Dervieux T , WesselsJA, KremerJM et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet. Genomics 22(1) , 1–9 (2012).
  • Coulthard LR , TaylorJC, EyreS et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann. Rheum. Dis. 70(1) , 98–103 (2011).
  • Potter C , CordellHJ, BartonA et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann. Rheum. Dis. 69(7) , 1315–1320 (2010).
  • Hess A , AxmannR, RechJ et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc. Natl Acad. Sci. USA 108(9) , 3731–3736 (2011).
  • Urano W , TaniguchiA, YamanakaH et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3) , 183–190 (2002).
  • Kurzawski M , PawlikA, SafranowK, HerczynskaM, DrozdzikM. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics8(11) , 1551–1559 (2007).
  • Taniguchi A , UranoW, TanakaE et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet. Genomics 17(6) , 383–390 (2007).
  • van Ede AE , LaanRF, BlomHJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 44(11) , 2525–2530 (2001).
  • Weisman MH , FurstDE, ParkGS et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 54(2) , 607–612 (2006).
  • Xiao H , XuJ, ZhouX et al. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis. Clin. Exp. Rheumatol. 28(5) , 728–733 (2010).
  • Choe JY , LeeH, JungHY, ParkSH, BaeSC, KimSK. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol. Int.32(6) , 1837–1842 (2012).
  • Caliz R , Del Amo J, Balsa A et al. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand. J. Rheumatol.41(1) , 10–14 (2012).
  • Berkun Y , LevartovskyD, RubinowA et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis. 63(10) , 1227–1231 (2004).
  • Hughes LB , BeasleyTM, PatelH et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65(9) , 1213–1218 (2006).
  • Kumagai K , HiyamaK, OyamaT, MaedaH, KohnoN. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med.11(5) , 593–600 (2003).
  • Taraborelli M , AndreoliL, ArchettiS, FerrariM, CattaneoR, TincaniA. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin. Exp. Rheumatol.27(3) , 499–502 (2009).
  • Mena JP , Salazar-ParamoM, Gonzalez-LopezL et al. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases. Pharmacogenomics J. 11(4) , 287–291 (2011).
  • Tasbas O , BormanP, Gurhan Karabulut H, Tukun A, Yorgancioglu R. The frequency of A1298C and C677T polymorphisms of the methylentetrahydrofolate gene in Turkish patients with rheumatoid arthritis: relationship with methotrexate toxicity. Open Rheumatol. J.5 , 30–35 (2011).
  • Iannaccone CK , LeeYC, CuiJ et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women‘s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology 50(1) , 40–46 (2011).
  • Sharma S , DasM, KumarA et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet. Genomics 19(10) , 823–828 (2009).
  • Jekic B , LukovicL, BunjevackiV et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur. J. Clin. Pharmacol. doi:10.1007/s00228-012-1341-3 (2012) (Epub ahead of print).
  • Berkun Y , Abou Atta I, Rubinow A et al. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J. Rheumatol.34(8) , 1664–1669 (2007).
  • Hider SL , ThomsonW, MackLF, ArmstrongDJ, ShadforthM, BruceIN. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology47(8) , 1156–1159 (2008).
  • van der Straaten RJ , WesselsJA, de Vries-Bouwstra JK et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics8(2) , 141–150 (2007).
  • Hayashi H , FujimakiC, DaimonT, TsuboiS, MatsuyamaT, ItohK. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J. Clin. Pharm. Ther.34(3) , 355–361 (2009).
  • Rizzo R , RubiniM, GovoniM et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet. Genomics16(9) , 615–623 (2006).
  • Baricordi OR , GovoniM, RizzoR, TrottaF. In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment. Ann. Rheum. Dis.66(8) , 1125–1126 (2007).
  • Stamp LK , O‘DonnellJL, ChapmanPT et al. Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1) , 154–155 (2009).
  • Kang CP , LeeKW, YooDH, KangC, BaeSC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology44(4) , 547–552 (2005).
  • Maxwell JR , PotterC, HyrichKL et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum. Mol. Genet. 17(22) , 3532–3538 (2008).
  • Chatzikyriakidou A , GeorgiouI, VoulgariPV, VenetsanopoulouAI, DrososAA. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients‘ response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology46(6) , 1034–1035 (2007).
  • Miceli-Richard C , CometsE, VerstuyftC et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann. Rheum. Dis. 67(4) , 478–484 (2008).
  • Vasilopoulos Y , BagiatisV, StamatopoulouD et al. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-alpha response in rheumatoid arthritis. Clin. Exp. Rheumatol. 29(4) , 701–704 (2011).
  • Mugnier B , BalandraudN, DarqueA, RoudierC, RoudierJ, RevironD. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum.48(7) , 1849–1852 (2003).
  • Fonseca JE , CarvalhoT, CruzM et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann. Rheum. Dis. 64(5) , 793–794 (2005).
  • Seitz M , WirthmullerU, MollerB, VilligerPM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology46(1) , 93–96 (2007).
  • Stojanovic S , Jevtovic-StoimenovT, StankovicA et al. [Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept]. Srp. Arh. Celok. Lek. 139(11–12) , 784–789 (2011).
  • Balog A , KlauszG, GalJ et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71(5) , 274–280 (2004).
  • Guis S , BalandraudN, BouvenotJ et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 57(8) , 1426–1430 (2007).
  • Marotte H , Pallot-PradesB, GrangeL et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann. Rheum. Dis. 65(3) , 342–347 (2006).
  • Criswell LA , LumRF, TurnerKN et al. The influence of genetic variation in the HLA–DRB1 and LTA–TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50(9) , 2750–2756 (2004).
  • Padyukov L , LampaJ, HeimburgerM et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62(6) , 526–529 (2003).
  • Ongaro A , De Mattei M, Pellati A et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol. Int.28(9) , 901–908 (2008).
  • Cuchacovich M , FerreiraL, AlisteM et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 33(4) , 228–232 (2004).
  • Pinto JA , RegoI, Rodriguez-GomezM et al. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA–DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 35(1) , 177–178 (2008).
  • Fabris M , Di Poi E, Sacco S, Damante G, Sinigaglia L, Ferraccioli G. [TNF- alpha gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-alpha agents: preliminary results]. Reumatismo54(1) , 19–26 (2002).
  • Bartelds GM , WijbrandtsCA, NurmohamedMT et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 60(8) , 2541–2542 (2009).
  • Schotte H , SchluterB, DryndaS et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(4) , 575–581 (2005).
  • Martinez A , SalidoM, BonillaG et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 50(4) , 1077–1082 (2004).
  • Potter C , HyrichKL, TraceyA et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1) , 69–74 (2009).
  • Morales-Lara MJ , CaneteJD, Torres-MorenoD et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 79(6) , 591–596 (2012).
  • Rooryck C , BarnetcheT, RichezC, LaleyeA, ArveilerB, SchaeverbekeT. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin. Exp. Rheumatol.26(2) , 340–342 (2008).
  • Toonen EJ , CoenenMJ, KievitW et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann. Rheum. Dis. 67(8) , 1174–1177 (2008).
  • Canete JD , SuarezB, HernandezMV et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68(10) , 1547–1552 (2009).
  • Tsukahara S , IkariK, SatoE et al. A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67(12) , 1791–1792 (2008).
  • Tutuncu Z , KavanaughA, ZvaiflerN, CorrM, DeutschR, BoyleD. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum.52(9) , 2693–2696 (2005).
  • Kastbom A , BrattJ, ErnestamS et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum. 56(2) , 448–452 (2007).
  • Okuyama A , NagasawaH, SuzukiK et al. Fcgamma receptor IIIB polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(2) , 299–304 (2011).
  • Tan RJ , GibbonsLJ, PotterC et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann. Rheum. Dis. 69(6) , 1029–1035 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.